Can a GLP-1 Pill Revive Novo Nordisk? | Prof G Markets

Quick Overview

Novo Nordisk's GLP-1 oral pill, Wegovy, which gained FDA approval on December 23, 2025, is experiencing massive adoption, with 1 in 8 American adults currently using GLP-1s, signaling a major shift in obesity treatment that may eventually challenge the market dominance of injectable GLP-1s like Eli Lilly's Zepbound.

Key Points: The FDA approved the oral GLP-1 pill, Wegovy, for weight loss on December 23, 2025, marking the first daily oral medication of its kind in the US. Current usage of GLP-1s is high, with 1 in 8 American adults (over 40 million people) currently using them as of 2022. The oral version of the drug is priced between $149 and $299 per month, a fraction of the price of injectables, which may spur adoption, especially since roughly one-third of adults fear needles. The oral GLP-1 market is predicted to be massive, potentially exceeding $100 billion in market cap, with Novo Nordisk's oral version being a major driver. Eli Lilly's Zepbound (an injectable GLP-1) is currently the leader, but Novo Nordisk's oral version competes by offering a non-needle alternative, potentially disrupting the market share. The analyst Jared Holtz suggests the oral format is a significant factor in adoption, as many patients fear needles, leading to a potential 'reverse-hype cycle' where the oral drug gains traction despite the initial focus on injectables. The success of Novo Nordisk's oral GLP-1 is seen as a major development that could pressure competitors like Eli Lilly and potentially lead to further large deals in the sector.

Context: The video features an interview between Ed Elson (host of Prof G Markets) and Jared Holtz, Healthcare Equity Strategist at Mizuho, discussing recent market developments, primarily focusing on Novo Nordisk's FDA approval of Wegovy as an oral pill for weight loss. The conversation also touches upon the broader GLP-1 market, including competitors like Eli Lilly's Zepbound, the high rate of needle phobia affecting patient adherence, and the expected market impact of a convenient oral alternative.